[Side effects of thrombolytic therapy in patients with myocardial infarction].
Agostoni
A
A
Istituto di Medicina Interna, Università degli Studi, Milano.
Gardinali
M
M
D000818:Animals; D016255:Anistreplase / Q000009:adverse effects; D000906:Antibodies / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D001920:Bradykinin / Q000187:drug effects; D003165:Complement System Proteins / Q000187:drug effects; D003238:Connective Tissue / Q000187:drug effects; D004347:Drug Interactions; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007962:Leukocytes / Q000187:drug effects; D009203:Myocardial Infarction / Q000188:drug therapy*; D010960:Plasminogen Activators / Q000009:adverse effects* / Q000276:immunology; D013300:Streptokinase / Q000009:adverse effects / Q000276:immunology; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects
D000906:Antibodies; D016255:Anistreplase; D003165:Complement System Proteins; D013300:Streptokinase; D010960:Plasminogen Activators; D014568:Urokinase-Type Plasminogen Activator; D001920:Bradykinin